bacterial meningitis
Medical emergency — antibiotics within 60 minutes. Empiric: ceftriaxone + vancomycin, + ampicillin if Listeria risk (>50, pregnancy, immunocompromise). Dexamethasone before or with the first antibiotic dose — mortality benefit in pneumococcal meningitis (European Dexamethasone Study (2002)). Add acyclovir if any encephalitic features. Blood cultures → antibiotics → then CT/LP; CT first only with specific indications.
bacterial meningitis empiric antibiotics
- blood cultures × 2 immediately; LP before antibiotics only if it causes no delay
- dexamethasone 10 mg IV q6h × 4 days — BEFORE or WITH first antibiotic dose
- ceftriaxone 2 g IV q12h — give first
- if age >50, pregnancy, or immunocompromised: ampicillin 2 g IV q4h — give second
- vancomycin 25–30 mg/kg IV load (~2 g), then per local protocol (continuous infusion or AUC-guided) — give last
- if encephalitis features (behaviour change, focal signs, seizures): acyclovir 10 mg/kg IV q8h
- ceftriaxone allergy: meropenem 2 g IV q8h + vancomycin — see penicillin allergy
- droplet precautions until 24 h of effective therapy
- tailor to CSF culture/PCR at 48–72 h; stop dexamethasone if not pneumococcal
Ceftriaxone-non-susceptible S. pneumoniae is uncommon but present in Canada — empiric vancomycin continues until susceptibilities return. Penicillin-resistant isolates are often ceftriaxone-susceptible → check the ceftriaxone MIC before continuing vancomycin.
when to suspect
Classic triad (fever + neck stiffness + altered mental status) is present in <50%, but absence of all three makes meningitis very unlikely (~99–100% sensitivity for ≥1 — Attia, JAMA. 1999).
| feature | meningitis | encephalitis |
|---|---|---|
| dominant early feature | fever, headache, neck stiffness | altered mental status, behaviour change |
| focal deficits / seizures | late | early |
| next step | as below | + acyclovir, MRI, HSV/VZV PCR |
- acute fever + headache + any of: neck stiffness, photophobia, altered consciousness, petechial/purpuric rash
- Kernig and Brudzinski signs: low sensitivity — absence does not exclude meningitis
- jolt accentuation: originally reported ~97% sensitive; later studies much lower — a negative test does not exclude meningitis
- meningococcaemia can present as purpura + shock without meningism
- fever + confusion/behaviour change with modest lymphocytic CSF → acyclovir now, HSV PCR, MRI temporal lobes; early HSV PCR can be falsely negative → repeat at 3–7 days if suspicion persists → encephalitis
- basal meningitis (cranial nerve palsies, long-tract signs, subacute course) → think TB, Listeria, Cryptococcus, syphilis, Lyme
CT before LP — indications
LP can proceed without CT in most patients. CT first only if (IDSA):
- focal neurological deficit
- new-onset seizure (within 1 week)
- papilloedema
- abnormal level of consciousness
- immunocompromised (HIV, transplant, immunosuppressive therapy)
- history of CNS disease (mass, stroke, focal infection)
A normal CT does not exclude raised ICP.
If CT is needed before LP → blood cultures → dexamethasone + empiric antibiotics → CT → LP. Pre-treatment lowers CSF culture yield within hours (meningococcus can sterilise within ~2 h), but cell count, protein, glucose, and PCR remain interpretable.
CSF interpretation
| parameter | bacterial | viral | TB |
|---|---|---|---|
| opening pressure | ↑↑ (>30 cm H₂O) | normal–↑ | ↑↑ |
| WBC | >1000 × 10⁶/L (neutrophilic) | 10–500 (lymphocytic) | 100–500 (lymphocytic) |
| protein | ↑↑ (>1.0 g/L) | normal–↑ | ↑↑ |
| glucose | ↓↓ (CSF:serum <0.4) | normal | ↓↓ |
| Gram stain | positive in 60–90% | negative | AFB rarely positive |
Send: cell count + differential, protein, glucose (paired serum), Gram stain, culture, HSV/enterovirus PCR, and multiplex PCR if available. Immunocompromised → add cryptococcal antigen.
Partially treated meningitis: lymphocytic CSF, lower protein, sterile cultures — mimics viral → send PCR and treat empirically.
empiric therapy — detail
by risk group
| patient group | likely organisms | empiric regimen |
|---|---|---|
| 18–50, immunocompetent | S. pneumoniae, N. meningitidis | ceftriaxone 2 g IV q12h + vancomycin |
| >50, pregnant, or immunocompromised | above + Listeria monocytogenes | ceftriaxone + vancomycin + ampicillin 2 g IV q4h (Listeria is intrinsically cephalosporin-resistant) |
| post-neurosurgical / shunt / drain | S. aureus, CoNS, C. acnes, Gram-negatives incl. Pseudomonas | meropenem 2 g IV q8h + vancomycin; no dexamethasone; ID consult |
| basilar skull fracture | S. pneumoniae, H. influenzae, GAS | ceftriaxone + vancomycin |
Give the β-lactam before vancomycin — earlier effective Gram-negative/pneumococcal cover (Amoah, Clin Infect Dis. 2021: β-lactam-first associated with lower mortality in bacteraemia).
Post-neurosurgical (healthcare-associated ventriculitis/meningitis, IDSA 2017):
- remove infected shunt/hardware → external ventricular drain; ± rifampicin for staphylococci on retained hardware
- avoid piperacillin-tazobactam (poor CNS penetration); ceftazidime/cefepime as definitive therapy once susceptibility confirmed
- reimplant a new shunt only after CSF cultures have been negative for 7–10 days (organism-dependent)
penicillin allergy
| allergy history | approach |
|---|---|
| immediate reaction to penicillin (incl. anaphylaxis) | ceftriaxone — no shared side chain |
| ceftriaxone allergy | meropenem 2 g IV q8h + vancomycin |
| SCAR, serum sickness, AIN, cytopaenia to any β-lactam | avoid all β-lactams → vancomycin + moxifloxacin (IDSA) ± TMP-SMX for Listeria; ID consult |
| Listeria cover needed + β-lactams avoided | TMP-SMX 5 mg/kg (TMP) IV q6h |
dexamethasone
European Dexamethasone Study (2002): dexamethasone 10 mg IV q6h × 4 days reduced mortality and unfavourable outcome in pneumococcal meningitis; also reduces hearing loss.
- give before or with first antibiotic dose; ESCMID allows starting up to 4 h after the first antibiotic dose — not beyond
- continue × 4 days if S. pneumoniae; stop if another pathogen confirmed or meningitis excluded
- not for post-neurosurgical meningitis
- Listeria: stop — associated with higher mortality in neurolisteriosis (MONALISA, Lancet Infect Dis. 2017)
- may lower vancomycin CSF penetration — some add rifampicin for ceftriaxone-resistant pneumococcus
targeted therapy once pathogen known
| organism | preferred | duration |
|---|---|---|
| S. pneumoniae — penicillin MIC ≤0.06 | penicillin G 4 MU IV q4h (or ceftriaxone) | 10–14 days |
| S. pneumoniae — penicillin-resistant, ceftriaxone-susceptible | ceftriaxone 2 g IV q12h alone | 10–14 days |
| S. pneumoniae — ceftriaxone-resistant (MIC >1) | ceftriaxone + vancomycin (± rifampicin) | 10–14 days |
| N. meningitidis | penicillin G or ceftriaxone | 7 days |
| L. monocytogenes | ampicillin 2 g IV q4h ± gentamicin | 21 days |
| H. influenzae | ceftriaxone 2 g IV q12h | 7 days |
| GBS | penicillin G or ampicillin | 14–21 days |
post-exposure prophylaxis
meningococcal contacts
- close contacts: household, room/bed-sharing, kissing/shared utensils, childcare contacts, HCWs with unprotected exposure to respiratory secretions (intubation, suctioning, mouth-to-mouth), airline passengers seated adjacent on flights ≥8 h
- chemoprophylaxis ideally within 24 h, up to 10 days after last exposure: ciprofloxacin 500 mg PO single dose, or rifampicin 600 mg PO q12h × 2 days, or ceftriaxone 250 mg IM single dose (preferred in pregnancy)
- immunoprophylaxis for close contacts when the serogroup is vaccine-preventable: Men-C-ACYW (A, C, Y, W) or 4CMenB (B), per NACI/public health
- notify public health immediately
Prepared 2026-10-18. Not yet verified — check every number against the sources.